Evaluation of Antral Biopsies Obtained in Normal

Status Completed

Clinical Trial Summary

Esophagogastroduodenoscopy (EGD) is commonly performed in patients presenting with abdominal pain and dyspeptic symptoms, serving as a valuable diagnostic and therapeutic tool. While various methods are available for biopsy sampling when mucosal pathology is observed during EGD, the practice of obtaining biopsies from endoscopically normal mucosa remains controversial. Although there is literature suggesting that routine biopsies from the antrum and duodenum for surveillance purposes increase costs, pathological findings can sometimes be detected in areas that appear normal on mucosal examination, leading to potential changes in treatment approach if biopsies are obtained. In this study, a retrospective evaluation of the prevalence of various pathologies detected in biopsies obtained from endoscopically normal mucosa in patients who underwent EGD was reported as normal.

Clinical Trial Description

Esophagogastroduodenoscopy (EGD) is a commonly used diagnostic tool in upper gastrointestinal system diseases. Its widespread use is facilitated by its minimally invasive nature, the possibility of therapeutic procedures, low complication rates, and broad applicability. Although there are numerous guidelines regarding approaches to endoscopic pathologies and diseases detected during esophagogastroduodenoscopy, the necessity of biopsy sampling from mucosal areas that are endoscopically normal remains controversial. In this study, patients aged between 18 and 95 who underwent EGD at the Sisli Hamidiye Etfal Training and Research Hospital Surgical Endoscopy Unit between 2021 and 2023, with no pathology detected during the endoscopic examination and who underwent biopsy sampling, will be evaluated. History of upper gastrointestinal surgery, detection of the endoscopic pathology, and not having biopsy sampling will be considered as exclusion criteria. The rate of detection of histopathological findings in the obtained biopsies, severity and activity of gastritis, rate and density of Helicobacter pylori detection, and rate and extent of intestinal metaplasia will be evaluated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06269380
Study type	Interventional
Source	Sisli Hamidiye Etfal Training and Research Hospital
Contact
Status	Completed
Phase	N/A
Start date	February 13, 2024
Completion date	February 21, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03554356` - Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)	N/A
Recruiting	`NCT01398579` - Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy	Phase 1
Completed	`NCT01614418` - Radiofrequency Ablation for Gastric Metaplasia and Dysplasia	Phase 1/Phase 2
Completed	`NCT06282484` - A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions
Not yet recruiting	`NCT06085677` - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Completed	`NCT01024621` - Confocal Laser Endomicroscopy for the Detection of Gastric Intestinal Metaplasia: a Randomized Controlled Trial	N/A
Terminated	`NCT05579444` - Systems Biology of Gastrointestinal and Related Diseases
Recruiting	`NCT04331951` - Sensitivity of Targeted Biopsy Within Sydney Protocol for GIM	N/A
Completed	`NCT03188406` - Gastric Cancer Precursor Lesions (GCPL) Study
Recruiting	`NCT05053945` - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Completed	`NCT02075905` - Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management	N/A
Completed	`NCT01374074` - Racial Disparity in Barrett's Esophagus	N/A
Recruiting	`NCT02457624` - Gastric Cancer Screening Quality Improvement System Establishment	N/A
Recruiting	`NCT05818072` - The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE	N/A
Completed	`NCT04296513` - Diagnosis of Gastritis, H. Pylori Infection and Atrophic Gastritis in Dyspeptic Patients
Completed	`NCT01896310` - New Classification of Stomach Using Probe-based Confocal Laser Endomicroscopy	N/A
Completed	`NCT01373125` - Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?	N/A
Completed	`NCT03976739` - Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study.
Recruiting	`NCT04054713` - Acetic Acid for the Detection of Esophageal Neoplasms	N/A
Terminated	`NCT02788214` - Helicobacter Pylori Genome Project (HpGP)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms